Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of Oncology, Cumming School of Medicine, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Ann Surg. 2022 Feb 1;275(2):e473-e478. doi: 10.1097/SLA.0000000000003938.
This study aimed to evaluate the association between prescribers' opioid prescribing history and persistent postoperative opioid use in cancer patients undergoing curative-intent surgery.
Study has shown that patients may be over-prescribed analgesics after surgery. However, whether and how the prescriber's opioid prescribing behavior impacts persistent opioid use is unclear.
All adults with a diagnosis of solid cancers who underwent surgery during the study period (2009-2015) in Alberta, Canada and were opioid-naïve were included. The key exposure was the historical opioid-prescribing pattern of a patient's most responsible prescriber. The primary outcome was "new persistent postoperative opioid user," was defined as a patient who was opioid-naïve before surgery and subsequently filled at least 1 opioid prescription between 60 and 180 days after surgery.
We identified 24,500 patients. Of these, 2106 (8.6%) patients became a new persistent opioid user after surgery. Multivariate analysis demonstrated that patients with most responsible prescribers that historically prescribed higher daily doses of opioids (≥50 vs <50 mg oral morphine equivalent) had an increased risk of new persistent opioid use after surgery (odds ratio = 2.41, P < 0.0001). In addition to the provider's prescribing pattern, other factors including younger age, comorbidities, presurgical opioid use, chemotherapy, type of tumor/surgical procedure were also found to be independently associated with new persistent postoperative opioid use.
Our results suggest that prescriber with a history of prescribing a higher opioid dose is an important predictor of persistent postoperative opioid use among cancer patients undergoing curative-intent surgery.
本研究旨在评估癌症患者接受根治性手术时,医生开具阿片类药物处方的历史与术后持续使用阿片类药物之间的相关性。
研究表明,患者在手术后可能会被过度开具止痛药。然而,医生的阿片类药物处方行为是否以及如何影响持续使用阿片类药物尚不清楚。
所有在研究期间(2009-2015 年)在加拿大艾伯塔省接受手术且阿片类药物初治的患有实体癌的成年人患者均纳入本研究。主要暴露因素为患者主要责任医生的历史阿片类药物处方模式。主要结局是“新的持续术后阿片类药物使用者”,定义为手术前未使用阿片类药物,且术后 60-180 天内至少开具 1 份阿片类药物处方的患者。
共纳入 24500 例患者。其中,2106 例(8.6%)患者术后成为新的持续阿片类药物使用者。多变量分析表明,主要责任医生的历史处方中阿片类药物日剂量较高(≥50 与<50mg 口服吗啡当量)的患者,术后发生新的持续阿片类药物使用的风险增加(比值比=2.41,P<0.0001)。除了医生的处方模式外,年龄较小、合并症、术前使用阿片类药物、化疗、肿瘤/手术类型等因素也与术后持续使用阿片类药物有关。
我们的研究结果表明,开具高剂量阿片类药物处方的医生是接受根治性手术的癌症患者术后持续使用阿片类药物的重要预测因素。